Skip to main content

Table 1 General features of patients with dermatomyositis

From: Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis

  Total
(n = 87)
Mi-2 (+)
(n = 17)
Mi-2 (−)
(n = 70)
P value
Age at disease diagnosis (years) 42.4 ± 13.8 43.1 ± 13.7 42.3 ± 14.0 0.819
Gender: female 64 (73.6) 13 (76.5) 41 (72.9) 1.000
Ethnicity: white 69 (79.3) 15 (88.2) 44 (77.1) 0.696
Disease duration (years) 4.3 [2.9–7.1] 4.5 [3.0–6.0] 4.3 [2.5–7.5] 0.945
Duration of follow-up time (years) 4.3 [2.9–7.1] 4.5 [3.0–6.0] 4.3 [2.5–7.5] 0.945
Constitutional symptoms (baseline) 52 (59.8) 11 (64.7) 41 (58.6) 0.786
Cumulative manifestations     
Cutaneous manifestations
 Gottron’s papules/sign 84 (96.6) 17 (100.0) 67 (95.7) 1.000
 Heliotrope rash 79 (90.8) 15 (88.2) 64 (91.4) 0.651
 Facial rash 58 (66.7) 14 (82.4) 44 (62.9) 0.247
 Raynaud’s phenomenon 40 (46.0) 10 (58.8) 30 (42.9) 0.294
  “V-neck” sign 39 (44.8) 9 (52.9) 30 (42.9) 0.412
  “Shawl” sign 21 (24.1) 5 (29.4) 16 (22.9) 0.752
 Vasculitis 19 (21.8) 1 (5.9) 18 (25.7) 0.103
 Ulcers 13 (14.9) 3 (17.6) 10 (14.3) 0.715
 Calcinosis 3 (3.4) 0 3 (4.3)
Dysphagia 43 (49.4) 11 (64.7) 32 (45.7) 0.279
Articular involvement 31 (35.6) 3 (17.6) 28 (40.0) 0.094
Pulmonary involvement 31 (35.6) 1 (5.9) 30 (42.9) 0.004
 Dyspnea 29 (33.3) 1 (5.9) 28 (40.0) 0.008
 Incipient interstitial lung disease 26 (29.9) 1 (5.9) 25 (35.7) 0.017
 Pulmonary fibrosis 7 (8.0) 0 7 (10.0)
  “Ground glass” 11 (12.6) 0 11 (15.7)
 Pneumomediastinum 2 (2.3) 0 2 (2.9)
Creatine phosphokinase (U/L) 992 [148–8040] 6240 [3800–9148] 484 [115–4880] 0.001
Aldolase (U/L) 18.5 [6.6–60.7] 60.0 [35.0–138.0] 12.1 [6.3–40.0] 0.002